紫杉类药物诱发周围神经病变的影响因素及药物治疗研究进展  

Advances in influential factor and drug treatment studies for taxane-induced peripheral neuropathy

作　　者：朱鋆芳 高敬林 赵浩鹏 郄宏鑫 高笑男 王明霞[1,2] ZHU Yunfang;GAO Jinglin;ZHAO Haopeng;QIE Hongxin;GAO Xiaonan;WANG Mingxia(Dept.of Clinical Pharmacology,the Fourth Hospital of Hebei Medical University,Shijiazhuang 050011,China;Hebei Provincial Key Laboratory of Tumor Microenvironment and Drug Resistance,Shijiazhuang 050011,China)

机构地区：[1]河北医科大学第四医院临床药理研究部,石家庄050011 [2]河北省肿瘤微环境与耐药重点实验室,石家庄050011

出　　处：《中国药房》2024年第3期374-378,共5页China Pharmacy

基　　金：国家科技重大专项(No.2020ZX09201006-003);河北省自然科学基金项目(No.H2021206432);河北省2020年度医学科学研究课题(No.20200105)。

摘　　要：紫杉类药物诱发的周围神经病变(TIPN)患者已达数百万例,且临床尚无有效的治疗手段或预防措施。TIPN的发生可能与紫杉类药物剂型、遗传和分子标志物、药物剂量及化疗周期、患者因素等有关。目前,治疗TIPN的药物主要包括抑制轴突变性类(如多沙唑嗪、坦索罗辛)、阻止线粒体功能受损类(如谷胱甘肽三硫化物、抗氧化剂α-硫辛酸)、改善内环境中钙失衡类(如芍药甘草汤、N型电压门控钙通道抑制剂IPPQ)、抑制神经炎症类(如趋化因子抑制剂、选择性白细胞介素8受体抑制剂DF2726A)等。未来进一步探索对症于不同诱发机制的药物治疗策略有望成为临床精准防治及个体化治疗TIPN的新方向。There are millions of patients with taxane-induced peripheral neuropathy(TIPN),and there is no effective treatment or prevention measure in clinical practice.The occurrence of TIPN may be related to the dosage form of paclitaxel drugs,genetic and molecular markers,drug dosage and chemotherapy cycle,patient factors,etc.At present,drugs for treating TIPN mainly include those that inhibit axonal degeneration(such as dosazosin,tamsulosin),prevent mitochondrial dysfunction(such as glutathione trisulfides,antioxidantsα-lipoic acid),improve calcium imbalance in the internal environment(Shaoyao gancao decoction,N-type voltage-gated calcium channel inhibitor IPPQ),and inhibit neuroinflammation(such as chemokine inhibitors and selective interleukin-8 receptor inhibitors DF2726A).Further exploration of drug treatment strategies targeting different induction mechanisms is expected to become a new direction for precise clinical prevention and personalized treatment of TIPN.

关 键 词：紫杉类药物 周围神经病变 影响因素 治疗药物 

分 类 号：R979.1[医药卫生—药品] R969.3[医药卫生—药学]